Here are the 10-K annual reports from ADMA Biologics, Inc. (ADMA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ADMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADMA filings page.
ADMA Biologics is a U.S. biopharmaceutical company focused on plasma-derived therapies for immunodeficient and immune‑compromised patients. It currently markets three FDA‑approved products: ASCENIV, an IVIG for primary humoral immunodeficiency, a second IVIG for PI in adults and children two years and older, and Nabi‑HB for Hepatitis B exposure.
ADMA manufactures at its Boca Raton facility, which it believes can support projected annual revenues greater than $635 million in 2026 and $775 million in 2027, with targeted Adjusted Net Income exceeding $255 million and $315 million and Adjusted EBITDA exceeding $360 million and $455 million, respectively. An FDA‑approved yield enhancement process is expected to increase ASCENIV and IVIG production yields by about 20%, with 2026 as the first full year of yield‑enhanced output. The company is divesting three plasma centers for $12.0 million while securing long‑term high‑titer plasma supply agreements, adopting its ADMAlytics AI platform across manufacturing and commercial operations, and advancing SG‑001, an S. pneumoniae hyperimmune candidate that could enter registrational trials after an anticipated pre‑IND submission in 2026.